INVO Insider Trading Activity and SEC Form 4 Filings
INVO insider trading summary
No open-market insider purchases or sales of INVO Bioscience, Inc. (INVO) have been reported on SEC Form 4 in the past 12 months.
Latest INVO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 1, 2022 | Andrea Goren | Chief Financial Officer | Buy | $50K (52,632 @ $0.95) |
| Jun 1, 2022 | Jeffrey Segal | Director | Buy | $9K (9,211 @ $0.95) |
| Jun 1, 2022 | Barbara Ryan | Director | Buy | $10K (10,526 @ $0.95) |
| Jun 1, 2022 | Rebecca Messina | Director | Buy | $9K (9,868 @ $0.95) |
| Jun 1, 2022 | Kevin Doody | Medical Director | Buy | $168K (177,306 @ $0.95) |
| Jun 1, 2022 | Matthew K Szot | Director | Buy | $14K (14,474 @ $0.95) |
| Jun 1, 2022 | Steve Shum | Chief Executive Officer | Buy | $56K (58,885 @ $0.95) |
| Jun 1, 2022 | Michael Jos. Campbell | Chief Operating Officer | Buy | $10K (10,526 @ $0.95) |
| Jun 1, 2022 | Trent D Davis | Director | Buy | $11K (11,184 @ $0.95) |
| Oct 5, 2021 | Andrea Goren | Chief Financial Officer | Buy | $100K (30,674 @ $3.26) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.